Skip to main navigation
logo
Logo

Site - Top Nav

  • About Iveric
  • Our Commitment
  • Why Iveric?
  • Clinical Programs
  • Investor Relations
  • Contact Us

Site - IR Nav

  • Investor Relations
  • News
  • Events & Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Results
    • Key Ratios
  • IRS Form 8937
  • Stock Information
    • Historic Stock Lookup
    • Investment Calculator
    • Analyst Coverage
  • Investor FAQs
  • Derivative Settlement
  • Contact Us

Press Releases

09.24.2013
Ophthotech Corporation Prices Initial Public Offering
08.29.2013
Ophthotech Enrolls First Patient in Phase 3 Clinical Trial of Fovista™ Anti-PDGF Therapy in Combination with Anti-VEGF Therapy for Wet AMD
08.15.2013
Ophthotech Corporation Files Registration Statement for Proposed Initial Public Offering
05.29.2013
Funding to Develop the First Therapy to Show Superior Efficacy Over the Current Standard of Care
01.03.2013
Ophthotech to Present at 31st Annual J.P. Morgan Healthcare Conference
10.24.2012
Positive Results from Phase 2b Study of Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ to be Presented at AAO Retina Subspecialty Day
06.13.2012
Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial
01.03.2012
Ophthotech to Present at 30th Annual J.P. Morgan Healthcare Conference

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Current page 28

Site - Shareholder Tools

Printed Materials
Printed Materials
Email Alerts
Email Alerts
Downloads
Downloads
RSS Feeds
RSS Feeds
Print
Print
Share This
Share This
Twitter
Twitter

Site - Footer Nav

  • Contact Us
  • Careers
  • Expanded Access
  • Privacy Policy
  • Sitemap